Hua Medicine Receives Milestone Payment from Bayer for Dorzagliatin
China-based Hua Medicine has announced receiving a RMB 400 million (USD 59 million) milestone payment...
China-based Hua Medicine has announced receiving a RMB 400 million (USD 59 million) milestone payment...
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving orphan drug designation (ODD) status...
China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II...
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving Abbreviated New Drug Application (ANDA) status...
China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received Abbreviated...
A strategic partnership between China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) and Bayer Consumer...
China’s Center for Drug Evaluation (CDE) has received a marketing approval application for Innovent Biologics...
Bayer’s (ETR: BAYN) women’s healthcare unit for the South China region is reportedly planning to...
Germany-based pharmaceutical giant Bayer AG (VIE: BAYN) released its Q2 2022 financial report, revealing a...
The National Medical Products Administration (NMPA) has approved Bayer’s (ETR: BAYN) Category 1 drug Kerendia...
Germany-based Bayer (ETR: BAYN) has announced a voluntary recall of a specific lot of its...